Sacituzumab govitecan-话题@MedSci

#Sacituzumab govitecan#

7篇内容 | 1359人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2183902, encodeId=eca221839029f, content=<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> <a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a> <a href='/topic/show?id=07051105205b' target=_blank style='color:#2F92EE;'>#II期研究#</a>, objectTitle=ANN ONCOL | TROPHY-U-01研究： sacituzumab govitecan用于铂类化疗和免疫检查点抑制剂后进展的转移性尿路上皮癌患者的安全性和疗效（Ⅱ期开放标签研究）, objectType=article, longId=810673, objectId=b5b38106e319, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240123/1706017066453_6145188.png, objectUrl=/article/show_article.do?id=b5b38106e319, replyNumber=0, likeNumber=71, createdTime=2024-01-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b5b38106e319, moduleTitle=ANN ONCOL | TROPHY-U-01研究： sacituzumab govitecan用于铂类化疗和免疫检查点抑制剂后进展的转移性尿路上皮癌患者的安全性和疗效（Ⅱ期开放标签研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5b38106e319)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1503750, encodeId=31081503e501e, content=<a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=62, createdTime=2022-09-13, rootId=0, userName=qingrejiedu, userId=613b9689188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503749, encodeId=a22a1503e49aa, content=<a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a>, objectTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, objectType=article, longId=737431, objectId=c616e3743158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c616e3743158, replyNumber=0, likeNumber=114, createdTime=2022-09-01, rootId=0, userName=qingrejiedu, userId=613b9689188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c616e3743158, moduleTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c616e3743158)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503748, encodeId=610f1503e48ed, content=<a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=120, createdTime=2021-10-18, rootId=0, userName=qingrejiedu, userId=613b9689188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503747, encodeId=f87c1503e4788, content=<a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a>, objectTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, objectType=article, longId=210410, objectId=eb7421041030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7421041030, replyNumber=0, likeNumber=81, createdTime=2021-04-26, rootId=0, userName=qingrejiedu, userId=613b9689188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7421041030, moduleTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7421041030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503746, encodeId=eba61503e46f0, content=<a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a>, objectTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, objectType=article, longId=191734, objectId=89b6191e3439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b6191e3439, replyNumber=0, likeNumber=81, createdTime=2020-04-10, rootId=0, userName=qingrejiedu, userId=613b9689188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b6191e3439, moduleTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b6191e3439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503745, encodeId=67751503e4570, content=<a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a>, objectTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, objectType=article, longId=185333, objectId=36af18533328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af18533328, replyNumber=0, likeNumber=109, createdTime=2019-12-29, rootId=0, userName=qingrejiedu, userId=613b9689188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af18533328, moduleTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af18533328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503744, encodeId=b6d01503e448e, content=<a href='/topic/show?id=aa671583088' target=_blank style='color:#2F92EE;'>#Sacituzumab govitecan#</a>, objectTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, objectType=article, longId=160705, objectId=9197160e05e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9197160e05e2, replyNumber=0, likeNumber=71, createdTime=2019-02-23, rootId=0, userName=qingrejiedu, userId=613b9689188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9197160e05e2, moduleTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9197160e05e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Sacituzumab govitecan

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#尿路上皮癌# #Sacituzumab govitecan# #II期研究#

ANN ONCOL | TROPHY-U-01研究： sacituzumab govitecan用于铂类化疗和免疫检查点抑制剂后进展的转移性尿路上皮癌患者的安全性和疗效（Ⅱ期开放标签研究）

2024-01-25发表于上海

qingrejiedu (审核中...)

前往app查看评论内容

#Sacituzumab govitecan#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2022-09-13

qingrejiedu (审核中...)

前往app查看评论内容

#Sacituzumab govitecan#

J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌

2022-09-01

qingrejiedu (审核中...)

前往app查看评论内容

#Sacituzumab govitecan#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2021-10-18

qingrejiedu (审核中...)

前往app查看评论内容

#Sacituzumab govitecan#

NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌

2021-04-26

qingrejiedu (审核中...)

前往app查看评论内容

#Sacituzumab govitecan#

FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌

2020-04-10

qingrejiedu (审核中...)

前往app查看评论内容

#Sacituzumab govitecan#

FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA

2019-12-29

qingrejiedu (审核中...)

前往app查看评论内容

#Sacituzumab govitecan#

NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌

2019-02-23

科室
- - 订阅+
  - 更多科室
工具
服务